New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
16:05 EDTSIEGY, DHRDanaher to acquire Siemens Healthcare Diagnostics' clinical microbiology unit
Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (DHR), announced that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (SIEGY). The microbiology business operates with an installed base of over 6,000 instruments globally. The transaction is expected to close in 1Q15.
News For DHR;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
09:16 EDTDHRDanaher price target raised to $93 from $85 at RW Baird
Subscribe for More Information
07:19 EDTDHRDanaher priced target raised to $94 from $88 at BofA/Merrill
Subscribe for More Information
December 11, 2014
06:04 EDTDHRDanaher sees FY15 adjusted EPS $4.35-$4.45, consensus $4.01
Subscribe for More Information
06:02 EDTDHRDanaher backs Q4 EPS view of $1.00-$1.04, consensus $1.02
December 9, 2014
13:45 EDTDHRDanaher to host investor and analyst meeting
Subscribe for More Information
06:52 EDTSIEGYSiemens CEO says won't spend aggressively on M&A, Reuters reports
Siemens CEO Joe Kaeser stated that the company will not spend its money too aggressively in M&A and instead focus on organic growth, fix underperforming units, and looks to increase R&D spending, reports Reuters, citing Kaeser. Reference Link
December 8, 2014
07:53 EDTDHRDanaher price target raised to $100 from $89 at Jefferies
Jefferies raised its price target for Danaher shares to $100 ahead of the company's investor day and keeps a Buy rating on the name. It expects an initial 2015 organic growth outlook of 3% and earnings guidance of $3.95 and ex-amortization $4.40. Jefferies keeps a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use